Drug Profile

Levonorgestrel transdermal - Agile Therapeutics

Alternative Names: AG 890; AG 900; AG-1000; Progestin-only

Latest Information Update: 29 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Agile Therapeutics
Class Hormonal contraceptives; Hormonal replacements; Norpregnanes; Progesterone congeners; Small molecules
Mechanism of Action Progesterone receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Pregnancy

Most Recent Events

26 Aug 2024 Agile Therapeutics has been acquired by Insud Pharma
03 Jan 2022 Levonorgestrel transdermal is still in Phase-II clinical trials in Pregnancy (Prevention) in USA (Transdermal), Agile Therapeutics pipeline, January 2022)
01 Mar 2021 Agile therapeutics plans a phase III trial for Pregnancy (Prevention) (Transdermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com